Knowledge (XXG)

Sarah Pett

Source 📝

153: 170:
Neuhaus, Jacqueline Jacobs, David R. Baker, Jason V. Calmy, Alexandra Duprez, Daniel La Rosa, Alberto Kuller, Lewis H. Pett, Sarah L. Ristola, Matti Ross, Michael J. Shlipak, Michael G. Tracy, Russell Neaton, James D. (2010).
301:
Seddiki, Nabila; Sasson, Sarah C.; Santner‐Nanan, Brigitte; Munier, Meeling; Bockel, David van; Ip, Susanna; Marriott, Debbie; Pett, Sarah; Nanan, Ralph; Cooper, David A.; Zaunders, John J. (2009).
545: 303:"Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease" 236:
Babiker, Abdel G Emery, Sean Fätkenheuer, Gerd Gordin, Fred M Grund, Birgit Lundgren, Jens D Neaton, James D Pett, Sarah L Phillips, Andrew Touloumi, Giota Vjechaj, Michael J (2013).
293: 228: 535: 525: 466: 119: 555: 540: 367: 550: 530: 59: 238:"Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study" 115: 145:
or a placebo through a drip for up to ten days of their stay in hospital. Pett showed that patients treated with
123: 79: 63: 138: 95: 32: 520: 287: 222: 173:"Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection" 133:
Pett led the Adaptive COVID-19 Treatment Trial (ACTT-EU/UK), a clinical trial into the efficacy of
340: 439: 391: 332: 324: 275: 257: 210: 192: 130: 87: 86:
of infections and the development of optimised treatment pathways for infections. During the
314: 265: 249: 200: 184: 111: 107: 83: 49: 270: 205: 514: 344: 490: 157: 146: 142: 134: 91: 328: 261: 253: 196: 415: 336: 279: 214: 126:. She was promoted to the Chair of the Infectious Diseases theme in 2016. 319: 302: 368:"UCL researchers lead trial to test remdesivir drug on COVID-19 patients" 237: 172: 188: 491:"COVID-19 Tied to Wide Range of Neuropsychiatric Complications" 467:"ACTT-EU/UK trial finds remdesivir speeds up COVID-19 recovery" 149:
recovered 31% faster than those who did not receive treatment.
90:, Pett led a clinical trial that investigated the efficacy of 55: 45: 28: 21: 16:British immunopathologist and COVID-19 researcher 546:Medical Research Council (United Kingdom) people 152:She has also been involved in research on the 8: 292:: CS1 maint: multiple names: authors list ( 227:: CS1 maint: multiple names: authors list ( 18: 318: 269: 204: 78:is a Professor of Infectious Diseases at 154:neurological complications from COVID-19 358: 536:Academics of University College London 285: 220: 526:Alumni of the University of Edinburgh 7: 461: 459: 177:The Journal of Infectious Diseases 14: 242:Clinical Trials (London, England) 471:MRC Clinical Trials Unit at UCL 444:MRC Clinical Trials Unit at UCL 396:MRC Clinical Trials Unit at UCL 307:European Journal of Immunology 141:. Adult inpatients were given 114:, where she led international 1: 556:21st-century women scientists 60:University of New South Wales 116:randomized controlled trials 82:. Pett is interested in the 541:British medical researchers 572: 118:. In 2013 Pett joined the 551:Women medical researchers 124:University College London 80:University College London 69: 64:University College London 38: 254:10.1177/1740774512440342 122:Clinical Trials Unit at 120:Medical Research Council 106:In 2000 Pett joined the 33:University of Edinburgh 160:that it may induce. 320:10.1002/eji.200838630 164:Selected publications 531:COVID-19 researchers 158:co-morbid conditions 137:as a treatment from 248:(1 Suppl): S5–S36. 139:coronavirus disease 102:Research and career 96:coronavirus disease 94:as a treatment for 366:UCL (2020-04-02). 183:(12): 1788–1795. 131:COVID-19 pandemic 88:COVID-19 pandemic 73: 72: 40:Scientific career 563: 505: 504: 502: 501: 487: 481: 480: 478: 477: 463: 454: 453: 451: 450: 436: 430: 429: 427: 426: 412: 406: 405: 403: 402: 388: 382: 381: 379: 378: 363: 348: 322: 297: 291: 283: 273: 232: 226: 218: 208: 19: 571: 570: 566: 565: 564: 562: 561: 560: 511: 510: 509: 508: 499: 497: 489: 488: 484: 475: 473: 465: 464: 457: 448: 446: 438: 437: 433: 424: 422: 416:"Dr Sarah Pett" 414: 413: 409: 400: 398: 390: 389: 385: 376: 374: 365: 364: 360: 355: 300: 284: 235: 219: 169: 166: 112:New South Wales 108:Kirby Institute 104: 84:immunopathology 62: 50:Immunopathology 29:Alma mater 24: 17: 12: 11: 5: 569: 567: 559: 558: 553: 548: 543: 538: 533: 528: 523: 513: 512: 507: 506: 482: 455: 431: 407: 383: 357: 356: 354: 351: 350: 349: 313:(2): 391–403. 298: 233: 189:10.1086/652749 165: 162: 103: 100: 71: 70: 67: 66: 57: 53: 52: 47: 43: 42: 36: 35: 30: 26: 25: 22: 15: 13: 10: 9: 6: 4: 3: 2: 568: 557: 554: 552: 549: 547: 544: 542: 539: 537: 534: 532: 529: 527: 524: 522: 521:Living people 519: 518: 516: 496: 492: 486: 483: 472: 468: 462: 460: 456: 445: 441: 435: 432: 421: 417: 411: 408: 397: 393: 387: 384: 373: 369: 362: 359: 352: 346: 342: 338: 334: 330: 326: 321: 316: 312: 308: 304: 299: 295: 289: 281: 277: 272: 267: 263: 259: 255: 251: 247: 243: 239: 234: 230: 224: 216: 212: 207: 202: 198: 194: 190: 186: 182: 178: 174: 168: 167: 163: 161: 159: 155: 150: 148: 144: 140: 136: 132: 127: 125: 121: 117: 113: 109: 101: 99: 97: 93: 89: 85: 81: 77: 76:Sarah L. Pett 68: 65: 61: 58: 54: 51: 48: 44: 41: 37: 34: 31: 27: 20: 498:. Retrieved 494: 485: 474:. Retrieved 470: 447:. Retrieved 443: 440:"Sarah Pett" 434: 423:. Retrieved 419: 410: 399:. Retrieved 395: 392:"Sarah Pett" 386: 375:. Retrieved 371: 361: 310: 306: 288:cite journal 245: 241: 223:cite journal 180: 176: 151: 128: 105: 75: 74: 56:Institutions 39: 129:During the 515:Categories 500:2024-06-17 476:2020-05-15 449:2024-06-17 425:2024-06-17 420:UNSW Sites 401:2020-05-15 377:2024-06-17 353:References 147:remdesivir 143:remdesivir 135:remdesivir 92:remdesivir 23:Sarah Pett 329:1521-4141 262:870252553 197:999829131 495:Medscape 372:UCL News 345:24793084 337:19180462 280:22547421 215:20446848 156:and the 271:3664112 206:2872049 343:  335:  327:  278:  268:  260:  213:  203:  195:  46:Fields 341:S2CID 333:PMID 325:ISSN 294:link 276:PMID 258:OCLC 229:link 211:PMID 193:OCLC 315:doi 266:PMC 250:doi 201:PMC 185:doi 181:201 110:in 98:. 517:: 493:. 469:. 458:^ 442:. 418:. 394:. 370:. 339:. 331:. 323:. 311:39 309:. 305:. 290:}} 286:{{ 274:. 264:. 256:. 246:10 244:. 240:. 225:}} 221:{{ 209:. 199:. 191:. 179:. 175:. 503:. 479:. 452:. 428:. 404:. 380:. 347:. 317:: 296:) 282:. 252:: 231:) 217:. 187::

Index

University of Edinburgh
Immunopathology
University of New South Wales
University College London
University College London
immunopathology
COVID-19 pandemic
remdesivir
coronavirus disease
Kirby Institute
New South Wales
randomized controlled trials
Medical Research Council
University College London
COVID-19 pandemic
remdesivir
coronavirus disease
remdesivir
remdesivir
neurological complications from COVID-19
co-morbid conditions
"Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection"
doi
10.1086/652749
OCLC
999829131
PMC
2872049
PMID
20446848

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑